## 2-(2-methyl-1H-indol-3-yl)ethanol: A Promising Compound for Research
**2-(2-methyl-1H-indol-3-yl)ethanol**, often abbreviated as **2-Me-TrpOH**, is an organic compound with a complex structure. It is a derivative of **tryptophan**, an essential amino acid, and shares some similarities with the neurotransmitter **serotonin**.
**Importance in Research:**
2-Me-TrpOH is attracting significant research interest due to its potential applications in various fields, including:
* **Neurology:**
* **Antidepressant activity:** Studies suggest that 2-Me-TrpOH might possess antidepressant properties by modulating serotonin pathways.
* **Neuroprotective effects:** Research indicates potential for 2-Me-TrpOH to protect neurons from damage, particularly in conditions like Parkinson's disease.
* **Modulation of cognitive function:** The compound could potentially improve cognitive performance by influencing neurotransmission in the brain.
* **Cancer Research:**
* **Anti-tumor activity:** 2-Me-TrpOH has shown promising results in preclinical studies for treating certain types of cancer by inhibiting tumor growth and promoting apoptosis (cell death).
* **Anti-angiogenesis:** The compound may suppress the formation of new blood vessels that nourish tumors, thus limiting their growth and spread.
* **Other potential applications:**
* **Anti-inflammatory effects:** 2-Me-TrpOH might exhibit anti-inflammatory properties, potentially beneficial for treating conditions like arthritis.
* **Anti-microbial activity:** Research suggests that the compound could possess antibacterial and antifungal properties.
**Current Research Status:**
While 2-Me-TrpOH shows significant promise, most research is still in preclinical stages. Further studies are needed to understand its mechanisms of action, efficacy, and safety in humans.
**Challenges and Future Directions:**
* **Pharmacokinetic profile:** Understanding how 2-Me-TrpOH is absorbed, distributed, metabolized, and excreted in the body is crucial for developing safe and effective treatments.
* **Toxicity and side effects:** Thorough evaluation of potential adverse effects is necessary before human trials.
* **Clinical trials:** Conducting well-designed clinical trials is essential to confirm the efficacy and safety of 2-Me-TrpOH for specific conditions.
**Conclusion:**
2-(2-methyl-1H-indol-3-yl)ethanol is a molecule with exciting potential for various therapeutic applications. Continued research efforts are necessary to translate its promising preclinical results into safe and effective treatments for human diseases.
ID Source | ID |
---|---|
PubMed CID | 659192 |
CHEMBL ID | 1430198 |
CHEBI ID | 111279 |
SCHEMBL ID | 7844388 |
Synonym |
---|
smr000040249 |
MLS000079794 |
CHEBI:111279 |
2-(2-methyl-1h-indol-3-yl)ethanol |
HMS2159O08 |
56895-60-4 |
1h-indole-3-ethanol, 2-methyl- |
HMS3353K19 |
AKOS022534000 |
SCHEMBL7844388 |
CHEMBL1430198 |
Q27190896 |
DTXSID00349744 |
FT-0750857 |
EN300-3186932 |
STL570364 |
2-(2-methyl-1h-indol-3-yl)ethan-1-ol |
CS-0246182 |
Class | Description |
---|---|
indoles | Any compound containing an indole skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 8.9125 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 44.6684 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 3.1623 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 3.1623 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 28.1838 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |